Related Experiment Video
Updated: Aug 29, 2025

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
Published on: April 4, 2018
PTPA variants and impaired PP2A activity in early-onset parkinsonism with intellectual disability
Christina Fevga1, Christelle Tesson2, Ana Carreras Mascaro1
1Department of Clinical Genetics, Erasmus University Medical Center Rotterdam, Erasmus MC, 3015 GD Rotterdam, The Netherlands.
Abstract:
The protein phosphatase 2A complex (PP2A), the major Ser/Thr phosphatase in the brain, is involved in a number of signalling pathways and functions, including the regulation of crucial proteins for neurodegeneration, such as alpha-synuclein, tau and LRRK2. Here, we report the identification of variants in the PTPA/PPP2R4 gene, encoding a major PP2A activator, in two families with early-onset parkinsonism and intellectual disability. We carried out clinical studies and genetic analyses, including genome-wide linkage analysis, whole-exome sequencing, and Sanger sequencing of candidate variants. We next performed functional studies on the disease-associated variants in cultured cells and knock-down of ptpa in Drosophila melanogaster. We first identified a homozygous PTPA variant, c.893T>G (p.Met298Arg), in patients from a South African family with early-onset parkinsonism and intellectual disability. Screening of a large series of additional families yielded a second homozygous variant, c.512C>A (p.Ala171Asp), in a Libyan family with a similar phenotype. Both variants co-segregate with disease in the respective families. The affected subjects display juvenile-onset parkinsonism and intellectual disability. The motor symptoms were responsive to treatment with levodopa and deep brain stimulation of the subthalamic nucleus. In overexpression studies, both the PTPA p.Ala171Asp and p.Met298Arg variants were associated with decreased PTPA RNA stability and decreased PTPA protein levels; the p.Ala171Asp variant additionally displayed decreased PTPA protein stability. Crucially, expression of both variants was associated with decreased PP2A complex levels and impaired PP2A phosphatase activation. PTPA orthologue knock-down in Drosophila neurons induced a significant impairment of locomotion in the climbing test. This defect was age-dependent and fully reversed by L-DOPA treatment. We conclude that bi-allelic missense PTPA variants associated with impaired activation of the PP2A phosphatase cause autosomal recessive early-onset parkinsonism with intellectual disability. Our findings might also provide new insights for understanding the role of the PP2A complex in the pathogenesis of more common forms of neurodegeneration.
Insights
New genetic variants in the PTPA gene cause early-onset parkinsonism and intellectual disability by impairing protein phosphatase 2A (PP2A) activation. These findings highlight PP2A
Area of Science:
- Neurogenetics
- Molecular Neuroscience
- Biochemistry
Background:
- Protein phosphatase 2A (PP2A) is a key Ser/Thr phosphatase in the brain, regulating neurodegeneration-associated proteins like alpha-synuclein, tau, and LRRK2.
- PP2A plays critical roles in various signaling pathways and cellular functions within the central nervous system.
Purpose of the Study:
- To identify the genetic cause of early-onset parkinsonism and intellectual disability in two families.
- To investigate the functional consequences of identified genetic variants on PP2A complex activity and neurodegenerative pathways.
Main Methods:
- Clinical evaluation and genetic analyses including genome-wide linkage analysis, whole-exome sequencing, and Sanger sequencing.
- Functional studies in cultured cells and Drosophila melanogaster models to assess variant effects on PTPA and PP2A.
- Assessment of motor symptoms and response to treatments like levodopa and deep brain stimulation.
Main Results:
- Identified homozygous PTPA variants (p.Met298Arg and p.Ala171Asp) co-segregating with disease in affected families.
- Both variants led to decreased PTPA RNA and protein stability, reduced PP2A complex levels, and impaired PP2A phosphatase activation.
- Knock-down of PTPA in Drosophila neurons caused locomotion deficits, which were reversed by L-DOPA treatment.
Conclusions:
- Bi-allelic missense PTPA variants impairing PP2A activation cause autosomal recessive early-onset parkinsonism with intellectual disability.
- The study provides insights into the role of the PP2A complex in neurodegeneration pathogenesis.
- Therapeutic strategies targeting PP2A may offer potential for treating parkinsonism and related neurodegenerative disorders.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

